pH-Sensitive Nanoparticles for Cytoplasmic Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nanoparticle drug carriers face issues with premature burst release, slow drug release, and low cellular uptake, leading to ineffective drug concentration in cancer cells due to drug resistance mechanisms, resulting in limited therapeutic efficacy and toxicity to healthy tissues.
Innovation Solution
Development of dually functionalized nanoparticles with a core of anticancer drugs and polymers soluble at lysosomal pH, combined with folic acid and cationic charges, enabling efficient internalization via multiple endocytosis mechanisms and rapid drug release within cancer cells, overcoming drug resistance and enhancing therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional drugs are administered intravenously, then the drug distributes throughout the body and reaches cancer tissues, but the drug concentration in cytoplasm is reduced by resistance mechanisms leading to treatment failure
Solution Approach 1:
The drug delivery system is segmented into distinct functional components: nanoparticles as carriers, folate receptors as targets, and endocytic pathways as delivery routes. This segmentation allows the drug to be transported in protected form to cancer cells and released intracellularly, overcoming extracellular efflux pumps and achieving effective cytoplasmic concentrations despite resistance mechanisms
Solution Approach 2:
The patent employs a nested structure where drugs are encapsulated within nanoparticles, which are then internalized by cancer cells through endocytosis. This nested arrangement protects the drug from extracellular efflux mechanisms and ensures delivery to the cytoplasm, where the drug can exert its therapeutic effect despite resistance to conventional administration
2Reliability
If nanoparticles are used for drug delivery, then drug selectivity for cancer is improved, but premature burst release occurs reducing therapeutic efficacy
Solution Approach 1:
The nanoparticle system exploits parameter changes in the cellular environment, specifically pH differences between extracellular and intracellular compartments. The nanoparticles remain stable in blood circulation but undergo structural changes or degradation upon entering the acidic endosomal/lysosomal environment, triggering controlled drug release only at the target site and preventing premature burst release
Solution Approach 2:
The nanoparticle acts as an intermediary carrier that protects the drug during circulation and mediates controlled release upon cellular internalization. The folate-receptor targeted nanoparticles serve as intermediaries that deliver the drug to cancer cells while preventing premature release, and the endocytic pathway acts as an intermediary mechanism that ensures intracellular delivery
3Ease of operation
If cancer cells take up drugs via diffusion and transport, then some drug enters cells, but efflux pumps remove drugs efficiently resulting in low cytoplasmic concentration
Solution Approach 1:
The nanoparticle system creates a copy or alternative pathway for drug entry that bypasses the normal diffusion and transport mechanisms vulnerable to efflux pumps. By utilizing folate-receptor mediated endocytosis, the drug is internalized in a protected form that efflux pumps cannot recognize or remove, effectively copying the entry process through a different route that avoids the harmful efflux mechanism
Solution Approach 2:
The invention extracts the drug from the vulnerable extracellular environment where efflux pumps operate and delivers it directly to the intracellular space. By encapsulating the drug in nanoparticles that are internalized via endocytosis, the system removes the drug from the domain of efflux pump action and places it directly into the cytoplasm, neutralizing the harmful effect of drug efflux
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles achieve high drug delivery to cancer cells, overcoming resistance and achieving therapeutic efficacy with minimal side effects by ensuring rapid and effective drug release above the cell-killing threshold.
Implementation Method 1
The outer shell is comprised of water-soluble polymer chains to shield the nanoparticle from recognition by the reticuloendothelial systems
Implementation Method 2
The core is comprised of the anticancer drug or drugs and polymer chains that are soluble at the lysosomal pH of the cancer cell
Implementation Method 3
The intermediate layer is comprised of polymer chains that are insoluble at the pH of healthy tissue, but soluble at the pH of the cancer interstitium
Implementation Method 4
the outer shell also includes folic acid moieties that enhance the absorption of the nanoparticles by cancer cells that are over-expressing folate receptors
Data Source
AI summary
The invention is a nanoparticle that contains an anticancer drug that is released in cancer cells when administered to a subject. The nanoparticles have a core including the anticancer drug and polymer chains that are soluble at the pH of the cancer cell. The core is surrounded by a layer of polymer chains that are insoluble at the pH of healthy tissue but soluble at the pH of the cancer interstitium. An outside layer is made of water-soluble polymer chains to shield the nanoparticle from RES recognition and give the nanoparticle a long circulation time in the bloodstream of the subject. The outside layer may also include folic acid moieties that bind folic acid receptors on the surface of the cancer cell.